Latest Medical Cannabis Industry News

Cann Group Limited reported a near break-even net operating cash flow for Q1 FY2026 and achieved its first EBITDA-positive month, setting the stage for a major debt restructure that will significantly reduce its borrowings.

Bioxyne Limited delivered a record FY25 with $30.4 million revenue, driven by Australian market growth and new European contracts. The company projects revenue up to $75 million in FY26, fueled by expanded production and international market entries.

Bioxyne Limited has reported record revenue and cash flow for FY25, driven by robust growth in the Australian medical cannabis market and strategic advances into Europe and the UK.

Bod Science Limited reports a dramatic reduction in half-year losses alongside revenue growth driven by a strategic shift to THC products. The company remains under a Deed of Company Arrangement with key corporate actions pending shareholder approval.